We are live on ! Find out more
AZN icon

AstraZeneca

390 hedge funds and large institutions have $7.26B invested in AstraZeneca in 2016 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 136 increasing their positions, 123 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more call options, than puts

Call options by funds: $30.9M | Put options by funds: $17.5M

11% more repeat investments, than reductions

Existing positions increased: 136 | Existing positions reduced: 123

1.41% more ownership

Funds ownership: 8.79%10.2% (+1.4%)

5% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 42

0% more funds holding

Funds holding: 390390 (0)

4% less capital invested

Capital invested by funds: $7.54B → $7.26B (-$277M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
390
Holders Change
Holders Change %
0%
% of All Funds
10.35%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
44
Increased
136
Reduced
123
Closed
42
Calls
$30.9M
Puts
$17.5M
Net Calls
+$13.4M
Net Calls Change
+$4.4M

AZN Hedge Fund Activity: Q1 2016 in Review

390 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2016, worth a combined $7.26B — down 3.7% from $7.54B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new AZN positions and 42 closed out — a net gain of 2 holders — while 136 added to existing stakes and 123 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $429M. The largest seller was Wellington Management Group, cutting an estimated $76.3M.

  • 390 institutional investors held AstraZeneca (AZN) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $7.26B of AstraZeneca stock for Q1 2016, down 3.7% quarter-over-quarter.
  • 44 funds opened new AstraZeneca positions in Q1 2016 and 42 closed out, a net change of +2 holders.
  • The largest AstraZeneca buyer in Q1 2016 was Dodge & Cox, an estimated $429M added.
  • The largest AstraZeneca seller in Q1 2016 was Wellington Management Group, an estimated $76.3M sold.

Based on aggregated 13F filings for Q1 2016.